AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28527133 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-264 1.8 mg/kg
Number of subjects: 43
Study 28528010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-Release Bimatoprost Ocular Ring
Number of subjects: 0
Study 28528010 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28528200 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma (SA)
Number of subjects: 0
Study 28528221 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal model
Number of subjects: 724
Study 28528221 — intervention group
Group type: EXPERIMENTAL
Intervention: 36-week model
Number of subjects: 724
Study 28528221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchopulmonary dysplasia (BPD)
Number of subjects: 724
Study 28528221 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 724
Study 28528431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rest/regadenoson stress CMR perfusion imaging protocol
Number of subjects: 26
Study 28528431 — intervention group
Group type: COMPARATOR
Intervention: X-ray coronary angiography
Number of subjects: 26
Study 28528767 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (RA)
Number of subjects: 8404
Study 28528767 — intervention group
Group type: COMPARATOR
Intervention: Femoral access (FA)
Number of subjects: 8404
Study 28528875 — intervention group
Group type: EXPERIMENTAL
Intervention: Central systolic BP
Number of subjects: 1599
Study 28528875 — intervention group
Group type: EXPERIMENTAL
Intervention: Central pulse pressure (PP)
Number of subjects: 1599
Study 28528875 — intervention group
Group type: COMPARATOR
Intervention: Brachial systolic BP
Number of subjects: 1599
Study 28528875 — intervention group
Group type: COMPARATOR
Intervention: Central augmentation pressure
Number of subjects: 1599
Study 28528875 — intervention group
Group type: EXPERIMENTAL
Intervention: E/E' and other echocardiographic parameters
Number of subjects: 1599
Study 28528917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o.
Number of subjects: 16
Study 28529313 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride and low-dose IL-2
Number of subjects: 81
Study 28529534 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat test meals with milk fat globule membrane (MFGM)
Number of subjects: 0
Study 28529534 — intervention group
Group type: COMPARATOR
Intervention: High saturated fat test meals without MFGM
Number of subjects: 0
Study 28529748 — intervention group
Group type: EXPERIMENTAL
Intervention: Local modulated electro-hyperthermia (mEHT) combined with traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, applied for 60 min every second day for 4 weeks (14 sessions); TCM decoction administered orally at 400 ml daily.
Number of subjects: 260
Study 28529748 — intervention group
Group type: COMPARATOR
Intervention: Standard intraperitoneal chemoinfusion (IPCI) with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m2).
Number of subjects: 260
Study 28530154 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided method
Number of subjects: 47
Study 28530154 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-guided method
Number of subjects: 47
Study 28530469 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcein acetoxymethyl (AM) dye for detecting vital bacteria; applied for 5 min incubation.
Number of subjects: 53
Study 28530469 — intervention group
Group type: COMPARATOR
Intervention: Colony-forming unit counting (control).
Number of subjects: 53
Study 28531175 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose liposomal amphotericin B (L-AmB) 10 mg/kg/week for 2 weeks
Number of subjects: 21
Study 28531175 — intervention group
Group type: COMPARATOR
Intervention: Matched untreated controls
Number of subjects: 21
Study 28531305 — intervention group
Group type: EXPERIMENTAL
Intervention: GADA (Glutamic Acid Decarboxylase)
Number of subjects: 994
Study 28531305 — intervention group
Group type: EXPERIMENTAL
Intervention: IAA (Insulin Autoantibodies)
Number of subjects: 994
Study 28531305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall progression to multiple autoantibodies
Number of subjects: 994
Study 28531305 — intervention group
Group type: EXPERIMENTAL
Intervention: Age breakpoints for GADA
Number of subjects: 994
Study 28531305 — intervention group
Group type: EXPERIMENTAL
Intervention: Age breakpoints for IAA
Number of subjects: 994
Study 28531309 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV antiretroviral therapy (ARV)
Number of subjects: 65
Study 28531455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats without sucrose
Number of subjects: 38
Study 28531455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats plus sucrose
Number of subjects: 38
Study 28531455 — intervention group
Group type: COMPARATOR
Intervention: Control (Cream of Rice)
Number of subjects: 38
Study 28531881 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP7.1 (45, 90, 150, and 200 mg/m²)
Number of subjects: 19
Study 28531881 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP7.1 (intravenous infusion for 5 consecutive days)
Number of subjects: 19
Study 28531881 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP7.1
Number of subjects: 19
Study 28532239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic recombinant factor VIII (rFVIII)
Number of subjects: 183
Study 28532434 — intervention group
Group type: EXPERIMENTAL
Intervention: NmA isolates from Cluster 1
Number of subjects: 23
Study 28532434 — intervention group
Group type: EXPERIMENTAL
Intervention: NmA isolates from Cluster 2
Number of subjects: 23
Study 28532434 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive meningococcal isolates
Number of subjects: 23
Study 28532434 — intervention group
Group type: EXPERIMENTAL
Intervention: Carried NmA isolates
Number of subjects: 23
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting at birth
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Current stunting
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting at birth by race
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting at birth by jurisdiction income level
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Current stunting by jurisdiction income level
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between stunting at birth and current stunting
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Current stunting and obesity
Number of subjects: 5558
Study 28532446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual burden of malnutrition
Number of subjects: 5558
Study 28532454 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood neutrophils from stable COPD patients
Number of subjects: 0
Study 28532454 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from one COPD group
Number of subjects: 0
Study 28532454 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 0
Study 28532489 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-concept for physical activity
Number of subjects: 224
Study 28532489 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood social life
Number of subjects: 224
Study 28532489 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood satisfaction
Number of subjects: 224
Study 28532489 — intervention group
Group type: EXPERIMENTAL
Intervention: Average social life
Number of subjects: 224
Study 28532489 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-concept for physical activity (within-person effect)
Number of subjects: 224
Study 28532489 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood social life (within-person effect)
Number of subjects: 224
Study 28532759 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Number of subjects: 0
Study 28532759 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28533916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 1 mg/kg once daily until no longer needing mechanical ventilation
Number of subjects: 120
Study 28533916 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 120
Study 28533941 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 36
Study 28534110 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organisation's Disability Assessment Schedule 2.0
Number of subjects: 262
Study 28535181 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg daily combined with paclitaxel 175 mg/m2 and carboplatin AUC 5 every 3 weeks for a maximum of four cycles followed by maintenance everolimus 5 mg daily until progression
Number of subjects: 49
Study 28535298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-Sofosbuvir plus Ribavirin (90 mg and 400 mg) for 12 weeks
Number of subjects: 111
Study 28535817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous transplantation of autologous bone marrow mesenchymal stromal cells (BMMSCs)
Number of subjects: 6
Study 28536088 — intervention group
Group type: EXPERIMENTAL
Intervention: Txt2Prevent intervention (text messaging program)
Number of subjects: 76
Study 28536088 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 28536126 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest intake of total sugars (median 137 g/d)
Number of subjects: 251261
Study 28536126 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest intake of fructose (median 35.2 g/d)
Number of subjects: 251261
Study 28536126 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest intake of sucrose (median 78 g/d)
Number of subjects: 251261
Study 28536126 — intervention group
Group type: COMPARATOR
Intervention: Lowest intake of total sugars (median 65 g/d)
Number of subjects: 251261
Study 28536126 — intervention group
Group type: COMPARATOR
Intervention: Lowest intake of fructose (median 9.7 g/d)
Number of subjects: 251261
Study 28536126 — intervention group
Group type: COMPARATOR
Intervention: Lowest intake of sucrose (median 25.8 g/d)
Number of subjects: 251261
Study 28536493 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Number of subjects: 564
Study 28536493 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 564
Study 28536944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous partial pressure of oxygen (PtcO2) monitoring
Number of subjects: 34
Study 28537061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg QD plus lamivudine 300 mg QD
Number of subjects: 20
Study 28538136 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-of-function variants in ANGPTL3
Number of subjects: 58335
Study 28538136 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab (human monoclonal antibody)
Number of subjects: 58335
Study 28538136 — intervention group
Group type: COMPARATOR
Intervention: Control antibody
Number of subjects: 58335
Study 28538984 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical claims identified events
Number of subjects: 12365
Study 28538984 — intervention group
Group type: COMPARATOR
Intervention: Physician adjudicated events
Number of subjects: 12365
Study 28539464 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin in combination with Weekly Paclitaxel
Number of subjects: 0
Study 28539464 — intervention group
Group type: COMPARATOR
Intervention: Weekly Paclitaxel
Number of subjects: 0
Study 28540640 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib, doses ranging from 50 to 225 mg every 24 hours and 75 to 275 mg every 12 hours
Number of subjects: 224
Study 28541060 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 74
Study 28541060 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 74
Study 28541071 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm message posters during the intervention phase
Number of subjects: 3
Study 28542316 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotics resumed until discharge
Number of subjects: 366
Study 28542316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 366
Study 28542316 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of AF
Number of subjects: 366
Study 28542316 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reinstitution of aspirin until discharge
Number of subjects: 366
Study 28542350 — intervention group
Group type: EXPERIMENTAL
Intervention: T0001
Number of subjects: 0
Study 28542350 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab and infliximab
Number of subjects: 0
Study 28542350 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study 28543053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks
Number of subjects: 52
Study 28543053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin
Number of subjects: 52
Study 28544782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphilimus sirolimus-eluting stents (A-SES)
Number of subjects: 1532
Study 28544782 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1532
Study 28544822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Control (TC) of inflammation
Number of subjects: 0
Study 28544822 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 0
Study 28544991 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood social environment attributes (collective efficacy and perceived crime)
Number of subjects: 6161
Study 28544991 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of economic development
Number of subjects: 6161
Study 28544991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of economic development
Number of subjects: 6161
Study 28545097 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model incorporating clinical risk factors and proteomic molecular markers
Number of subjects: 222
Study 28545097 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk factors
Number of subjects: 222
Study 28545097 — intervention group
Group type: COMPARATOR
Intervention: Proteomic molecular markers
Number of subjects: 222
Study 28545535 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback with action implementation toolbox
Number of subjects: 0
Study 28545535 — intervention group
Group type: COMPARATOR
Intervention: Feedback without action implementation toolbox
Number of subjects: 0
Study 28545546 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified milk fat (40g)
Number of subjects: 16
Study 28545546 — intervention group
Group type: COMPARATOR
Intervention: Unemulsified milk fat (40g)
Number of subjects: 16
Study 28545575 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 40
Study 28545575 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter-accelerometer recording
Number of subjects: 40
Study 28545923 — intervention group
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN 0.5mL
Number of subjects: 315
Study 28546135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with 5 days of hypofractionated radiotherapy (25 Gy in 5 fractions) during the second cycle of doxorubicin.
Number of subjects: 0
Study 28546135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with hypofractionated RT.
Number of subjects: 0
Study 28546135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated RT combined with chemotherapy.
Number of subjects: 0
Study 28546272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 0
Study 28546272 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28546279 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pulmonary obstruction detected through perfusion lung scanning after 6 months.
Number of subjects: 647
Study 28546279 — intervention group
Group type: COMPARATOR
Intervention: No residual pulmonary obstruction (control group).
Number of subjects: 647
Study 28546463 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day plus Prednisone 5 mg b.i.d.
Number of subjects: 8
Study 28546581 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat (PAN) 30 mg plus Azacitidine (AZA) 75 mg/m²
Number of subjects: 113
Study 28546581 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine (AZA) monotherapy
Number of subjects: 113
Study 28546877 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid Medical Foods
Number of subjects: 0
Study 28546877 — intervention group
Group type: COMPARATOR
Intervention: Glycomacropeptide Medical Foods
Number of subjects: 0
Study 28547132 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic participants (n=24)
Number of subjects: 24
Study 28547132 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and sex-matched volunteers (n=24)
Number of subjects: 24
Study 28547872 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI procedure
Number of subjects: 119
Study 28547872 — intervention group
Group type: EXPERIMENTAL
Intervention: High white matter lesion (WML) burden
Number of subjects: 119
Study 28547872 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular WML burden
Number of subjects: 119
Study 28547918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus weight loss (AEX+WL)
Number of subjects: 104
Study 28547918 — intervention group
Group type: COMPARATOR
Intervention: Weight loss (WL)
Number of subjects: 104
Study 28548886 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular compliers (RC) (≥2 PIMT/year)
Number of subjects: 115
Study 28548886 — intervention group
Group type: EXPERIMENTAL
Intervention: Erratic compliers (EC) (<2 PIMT/year)
Number of subjects: 115
Study 28548886 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliers (NC) (no PIMT)
Number of subjects: 115
Study 28548886 — intervention group
Group type: EXPERIMENTAL
Intervention: PIMT compliance
Number of subjects: 115
Study 28548886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucositis
Number of subjects: 115
Study 28548886 — intervention group
Group type: EXPERIMENTAL
Intervention: PD, PI, BOP, MR, SUP
Number of subjects: 115
Study 28549082 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion in patients with frontal brain tumours
Number of subjects: 40
Study 28549082 — intervention group
Group type: COMPARATOR
Intervention: Schnider model
Number of subjects: 40
Study 28549082 — intervention group
Group type: COMPARATOR
Intervention: Eleveld volunteer model
Number of subjects: 40
Study 28549082 — intervention group
Group type: COMPARATOR
Intervention: Marsh model
Number of subjects: 40
Study 28549082 — intervention group
Group type: COMPARATOR
Intervention: Eleveld patient model
Number of subjects: 40
Study 28549424 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive behavior therapy (ePlus) for 12 weeks
Number of subjects: 13
Study 28549424 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive behavior therapy (ePlus)
Number of subjects: 13
Study 28549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BCVA of 20/25 or better
Number of subjects: 259
Study 28549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BCVA between 20/25 and 20/70
Number of subjects: 259
Study 28549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BCVA between 20/70 and 20/200
Number of subjects: 259
Study 28549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BCVA worse than 20/200
Number of subjects: 259
Study 28549516 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 259
Study 28549834 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 132
Study 28550003 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mobile health platform with smart card technology
Number of subjects: 300
Study 28550003 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart card acceptability among pregnant women
Number of subjects: 300
Study 28550003 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart card usability by pregnant women and health facilities
Number of subjects: 300
Study 28550039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg, days 1, 8, and 15 of 28-day cycles for up to 12 cycles)
Number of subjects: 27
Study 28550039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg) with oral dexamethasone (40 mg, days 1-4) for patients with less than partial response after 3 cycles
Number of subjects: 27
Study 28550039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg)
Number of subjects: 27
Study 28550098 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered exoskeleton driven by a brain-computer interface (BCI) used at home for 12 weeks
Number of subjects: 10
Study 28550098 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered exoskeleton driven by a brain-computer interface (BCI)
Number of subjects: 10
Study 28550192 — intervention group
Group type: EXPERIMENTAL
Intervention: Khorana score
Number of subjects: 876
Study 28550192 — intervention group
Group type: EXPERIMENTAL
Intervention: PROTECHT score
Number of subjects: 876
Study 28550192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna score
Number of subjects: 876
Study 28550439 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 103
Study 28551166 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-2 visual fields
Number of subjects: 775
Study 28551359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks)
Number of subjects: 97
Study 28551430 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28
Study 28551430 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (group training setting)
Number of subjects: 28